Delivery Order SPE2DB24D2003-SPE2DB25FXLN9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $45,830.70 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pen injectors (0.5 mL units). This firm fixed-price delivery order, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive award under an existing contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is...
- The Defense Logistics Agency awarded a $5,441.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Mounjaro 15 mg/0.5 ml pen injectors (0.5 ml). The contract, which represents a non-set-aside competitive award, is scheduled for completion by July 22, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $5,441.80 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Mounjaro 2.5 mg/0.5 mL pen injectors (0.5 mL). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 13, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro 12.5 mg/0.5 mL pen injectors (0.5 mL). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,255.10 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 ml pen injectors on July 30, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 31, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Mounjaro is a prescription medication used for diabetes management, consistent with the...
- The Defense Logistics Agency awarded a $14,309.49 delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is categorized as a child contract under AmerisourceBergen's larger contract vehicle. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,577.37 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 ml pen (0.5 ml) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a injectable medication used in diabetes management, and this order represents a routine...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,162.70 for Mounjaro 7.5 mg/0.5 ml pen auto-injectors on July 23, 2025, with completion targeted for July 24, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, representing part of the company's...
- The Defense Logistics Agency awarded a delivery order valued at $11,918.20 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injectors on August 7, 2025, with completion scheduled for August 8, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription medication used for diabetes management, representing AmerisourceBergen's continued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $10,431.03 delivery order on July 25, 2025, for Mounjaro 12.5 mg/0.5 ml pen injectors, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLN9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,453.10 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside contract was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. Mounjaro is a diabetes medication used in military and veteran healthcare systems as part of the federal medical supply chain managed by DLA. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling value through December 2026. This prime vendor contract enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical commodities to support Defense Health Agency operations and other federal healthcare systems globally. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated consistent capability to fulfill federal medical procurement requirements through competitive awards across multiple therapeutic domains, including specialty medications, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/11/25 |